Trifecta Capital Advisors LLC Grows Stock Holdings in Johnson & Johnson $JNJ

Trifecta Capital Advisors LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 64.5% during the 2nd quarter, Holdings Channel reports. The fund owned 4,021 shares of the company’s stock after purchasing an additional 1,576 shares during the period. Trifecta Capital Advisors LLC’s holdings in Johnson & Johnson were worth $614,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in JNJ. Vanguard Group Inc. lifted its stake in shares of Johnson & Johnson by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 233,962,679 shares of the company’s stock valued at $38,800,371,000 after purchasing an additional 1,170,120 shares during the period. Northern Trust Corp lifted its stake in shares of Johnson & Johnson by 0.4% in the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock valued at $5,131,723,000 after purchasing an additional 130,645 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Johnson & Johnson by 26.4% in the 1st quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company’s stock valued at $3,844,580,000 after purchasing an additional 4,842,582 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Johnson & Johnson by 3.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 18,899,263 shares of the company’s stock valued at $3,133,602,000 after purchasing an additional 712,181 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Johnson & Johnson by 2.5% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 18,282,410 shares of the company’s stock valued at $3,031,955,000 after purchasing an additional 448,666 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $176.00 to $178.00 and gave the stock an “equal weight” rating in a research report on Friday. JPMorgan Chase & Co. upped their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 16th. Weiss Ratings upgraded shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday. UBS Group set a $198.00 price objective on shares of Johnson & Johnson in a research report on Friday, October 3rd. Finally, Citigroup upped their price objective on shares of Johnson & Johnson from $200.00 to $213.00 and gave the stock a “buy” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $192.94.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $190.66 on Friday. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $192.10. The firm has a market capitalization of $459.16 billion, a price-to-earnings ratio of 20.39, a PEG ratio of 2.40 and a beta of 0.40. The company has a fifty day simple moving average of $178.48 and a 200-day simple moving average of $163.76. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $24.02 billion during the quarter. On average, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.7%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.